SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-060288
Filing Date
2023-11-07
Accepted
2023-11-07 16:19:25
Documents
58
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q janx-20230930.htm   iXBRL 10-Q 2779318
2 EX-31.1 janx-ex31_1.htm EX-31.1 19448
3 EX-31.2 janx-ex31_2.htm EX-31.2 18232
4 EX-32.1 janx-ex32_1.htm EX-32.1 16397
  Complete submission text file 0000950170-23-060288.txt   10827272

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT janx-20230930_def.xml EX-101.DEF 202318
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT janx-20230930_cal.xml EX-101.CAL 47700
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20230930_lab.xml EX-101.LAB 427619
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20230930.xsd EX-101.SCH 48974
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20230930_pre.xml EX-101.PRE 308203
52 EXTRACTED XBRL INSTANCE DOCUMENT janx-20230930_htm.xml XML 2524137
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40475 | Film No.: 231384226
SIC: 2834 Pharmaceutical Preparations